FDA and CMS are trying to make personalized gene therapy workable at scale
Federal policy is catching up to a treatment model that does not fit neatly inside a standard drug dossier. The FDA has issued draft guidance for developers of individualized genome editing products for rare genetic diseases, while CMS plans to widen its Cell and Gene Therapy Access Model beyond sickle cell disease. Together, the two moves address the same bottleneck from opposite directions: how to approve highly customized therapies without forcing every patient-specific version through a full new development program, and how to pay for them without turning each state Medicaid program into a separate negotiation.
The FDA guidance, titled “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management,” centers on a regulatory structure called the Individualized Feature Space. In plain clinical terms, the concept creates predefined boundaries for how a genome editing product may vary from one patient to the next while still living inside a single biologics license application. If a new patient-specific variant stays within those guardrails and laboratory assays demonstrate adequate safety and activity, sponsors could add it to the application without launching a fresh clinical trial for each version.
One sentence captures the policy shift plainly: the regulator is trying to move from case-by-case exception handling to a repeatable approval framework.
A regulatory template for therapies built one patient at a time
Personalized genome editing is unlike conventional pharmacology. A small-molecule drug can be manufactured to exact chemical specifications and tested in a broad population, but a customized therapy may be designed for a single mutation, a single patient, or a narrow set of molecular features. That creates a structural problem for review: the product changes, but the disease logic remains related enough that sponsors and regulators need a common standard for deciding when a new variant is close enough to an already reviewed construct.
The FDA’s approach suggests that analytical assays will carry more of the evidentiary load than they do in traditional drug development. If the safety profile and biologic activity can be established in pre-specified testing, the agency appears willing to use those data as the bridge between one individualized therapy and the next. For rare disease programs, especially those aimed at ultra-small patient populations, that could reduce the need to repeat the same clinical work over and over when the molecular differences are modest and the treatment platform is otherwise unchanged.
The timing matters for hospital pharmacies, gene therapy centers, and academic medical programs that may eventually have to operationalize these products. Every individualized therapy adds complexity in manufacturing coordination, release testing, chain-of-custody management, and postapproval surveillance. A single application framework could make those workflows more predictable, especially if hospitals are expected to manage therapies that arrive as bespoke interventions rather than mass-produced inventory.
CMS is widening access before the reimbursement bottleneck hardens
CMS is moving on a parallel track. The agency said it will invite manufacturers of therapies for other conditions to apply to its Cell and Gene Therapy Access Model, a voluntary program in which CMS negotiates outcomes-based agreements with manufacturers for state Medicaid programs. The initial model focused on sickle cell disease, and its first evaluation found that CMS-led negotiations eased administrative burden for states and improved their leverage by pooling beneficiaries.
For Medicaid programs, that pooling effect is not a minor administrative detail. Ultra-expensive gene therapies can overwhelm state-by-state purchasing power, especially when only a small number of patients are eligible in any given jurisdiction. Centralized negotiation can reduce duplication, create a more consistent framework for outcomes tracking, and help states avoid building bespoke contracting infrastructure for every separate therapy. CMS also plans to release a request for applications in the coming months so negotiations can begin sooner after a therapy is approved, and it will accept applications for products already on the market.
The model matters because gene therapy reimbursement is not just a budget issue; it is a delivery issue. If coverage is slow, access stalls even when the science is ready. If contracts are fragmented, adoption becomes patchy across Medicaid programs, and patients with rare disease can end up facing geography-driven treatment delays.
Sickle cell experience is shaping the next phase of rare disease policy
Recent experience with sickle cell gene therapies is clearly influencing federal planning. The CMS model launched with Casgevy and Lyfgenia in 2025, and 33 states, the District of Columbia, and Puerto Rico joined the program, covering about 84% of Medicaid beneficiaries with sickle cell disease. That scale shows what can happen when the federal government aggregates demand rather than leaving each state to negotiate in isolation.
The FDA has been building toward this moment as well. In February, the agency unveiled a pathway for ultra-rare disease therapies, and this month it launched a rare disease framework initiative. Philadelphia-based Children’s Hospital of Philadelphia treated the first patient in the world with a personalized CRISPR therapy in 2025, and the FDA this year expanded approval of Casgevy to children as young as 2. Each of those steps signals the same underlying pressure: the therapeutic pipeline is becoming more individualized faster than old regulatory and payment systems can absorb.
For clinicians, this is more than policy housekeeping. If individualized gene editing products can be reviewed within a defined feature space, and if payment models can be negotiated in advance across state Medicaid programs, the path from bench to bedside shortens. The main clinical consequence is not theoretical access; it is whether a child or adult with a rare mutation can receive a tailored therapy before irreversible disease progression narrows the benefit window.
The open questions sit in execution rather than concept. FDA still has to define how broad that feature space can be without weakening assurance of safety and activity, and CMS still has to prove that outcomes-based contracting works beyond sickle cell disease without overwhelming states or manufacturers. Those details will determine whether personalized gene therapy becomes a durable treatment category or remains a series of isolated successes.